查詢結果分析
相關文獻
- BRAF Mutation in Papillary Thyroid Carcinoma: Pathogenic Role and Clinical Implications
- 甲狀腺髓質癌的細胞學表徵--初報
- Dermatofibrosarcoma Protuberans of the Scalp--Case Report
- 一例多發性頭頸癌之診斷與治療--病例報告
- 甲狀腺結節之細針穿刺細胞學篩檢
- Multinodular Goiter, Concomitant Microcarcinoma and Lymphocytic Thyroiditis Manifesting as Thyroid Autonomy
- A Pathological Complete Response after Nivolumab Therapy for Unresectable Sigmoid Colon Cancer with Microsatellite Instability-high Status and BRAF Mutation: A Case Report
頁籤選單縮合
題 名 | BRAF Mutation in Papillary Thyroid Carcinoma: Pathogenic Role and Clinical Implications=甲狀乳突狀癌的BRAF突變 : 致病機轉和臨床意義 |
---|---|
作 者 | 鄧錦泉; 李建賢; | 書刊名 | Journal of the Chinese Medical Association |
卷 期 | 73:3 2010.03[民99.03] |
頁 次 | 頁113-128+CA21 |
分類號 | 415.931 |
關鍵詞 | BRAF突變; 細針穿刺細胞學檢查; 甲狀腺乳突狀癌; BRAF mutation; Fine-needle aspiration cytology; Papillary thyroid cancer; |
語 文 | 英文(English) |
英文摘要 | Papillary thyroid cancer (PTC) is the most common endocrine malignancy, accounting for 85–90% of all thyroid cancers. Genetic alternations involving the mitogen-activated protein kinase (MAPK) pathway are frequently demonstrated in PTC, such as RET/PTC, RAS, and B-type Raf kinase (BRAF) mutations. Over 90% of BRAF mutations are T1799A, resulting in a BRAFV600E mutation. BRAFV600E is present in ∼50% of PTC and also found in aggressive histologic variants and PTC-derived anaplastic thyroid cancer, but is rare in follicular variants, and not found in follicular thyroid cancer. The tumorigenic role of BRAFV600E in the development of PTC was documented in thyroid-targeted BRAFV600E transgenic mice, and rat thyroid cells overexpressed with BRAFV600E suggested that BRAFV600E is an initiator of tumorigenesis and is required for tumor progression in PTC. Most clinical studies have demonstrated an association of BRAFV600E mutation with aggressive clinicopathologic characteristics and high tumor recurrence, although the results are controversial. The association is also observed in patients with papillary thyroid microcarcinomas and low-risk PTC. As a highly specific and unique mutation in PTC, testing for BRAFV600E in fine-needle aspiration specimens has been shown to refine the diagnostic accuracy of PTC in indeterminate cytology. Preoperative BRAFV600E analysis in low-risk patients may provide important value for prognostication, and these patients might benefit from receiving more intensive management and frequent follow-up. BRAF-targeted therapies have been developed to treat various human cancers including advanced thyroid cancers. Preclinical results are encouraging, but the anticancer effects of clinical trials are disappointing. Studies of multi-kinase inhibitors and/or combination with other regimens are underway in the treatment of advanced thyroid cancers. In this article, we review the pathogenesis of PTC, and the clinical implications of BRAFV600E mutation in the diagnosis, prognosis and potential targeted therapeutic strategies for thyroid cancers. |
本系統中英文摘要資訊取自各篇刊載內容。